

February 5, 2021

Via Electronic Submission

Division of Nuclear Material Safety
U.S. Nuclear Regulatory Commission Region I
2100 Renaissance Blvd Suite 100
King of Prussia, PA 19406

Subject: Confirmation of Closing of Transaction between Lantheus and PharmaLogic Holdings Corp. (Mail Control Numbers 624028 and 624029)
NRC License Number: 52-25361-02 (Docket No.: 030-38114)
NRC License Number: 52-25361-01-MD (Docket No.: 030-34187)

Dear Administrator:


In follow up to the NRC's Acceptance of Notification of Indirect License Transfers dated January 26, 2021, the undersigned hereby confirm that the Securities Purchase Agreement transaction set forth in the filings and letters to the NRC dated December 10, 2020 and January 13, 2021 (the "Letters") has closed on the terms disclosed in such Letters. Following the closing of the transaction, Lantheus MI Radiopharmaceuticals, Inc. is the holder of both licenses referenced above (namely NRC License Number 52-25361-02 (formerly held by Lantheus Medical Imaging, Inc.) and NRC License Number 52-25361-01-MD (held by Lantheus MI Radiopharmaceuticals, Inc.) and is also a wholly-owned subsidiary of PharmaLogic Holdings Corp.

If you have any questions or comments or require additional information pertaining to this transaction, please contact Lantheus' counsel for nuclear regulatory matters, Laura Plourde at Laura.Plourde@Lantheus.com or 617-935-1543.

[Remainder of Page Left Blank/ Signature Pages Follows]

I declare under penalty of perjury under the laws of the United States of America that to the best of my knowledge the information contained in this Letter pertaining to Lantheus Holdings, Inc. and its affiliated companies is true and correct.

Executed on February 5, 2021

A handwritten signature in black ink, appearing to read 'JBolla', is written over a solid horizontal line.

John Bolla, Chief Operating Officer

Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Address for Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.:

331 Treble Cove Rd

Billerica, Ma 01862

I declare under penalty of perjury under the laws of the United States of America that to the best of my knowledge the information contained in this Letter pertaining to PharmaLogic Holdings Corp. and its companies (including Lantheus MI Radiopharmaceuticals, Inc.) is true and correct.

Executed on February 8, 2021



Glen Palmer, Chief Operations Officer
PharmaLogic Holdings Corp. and Lantheus MI Radiopharmaceuticals, Inc.